AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
- First Posted Date
- 2005-05-24
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 456
- Registration Number
- NCT00111540
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-20
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT00108823
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kingdom, United Kingdom
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00108004
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-08
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT00107731
- Locations
- 🇬🇧
Research Site, Welwyn Garden City, United Kingdom
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00107107
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
- First Posted Date
- 2005-02-18
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00103935
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT00099619
- Locations
- 🇵🇱
Research Site, Lublin, Poland
PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT00099580
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
- First Posted Date
- 2004-12-14
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 736
- Registration Number
- NCT00099437
- Locations
- 🇻🇪
Research Site, Caracas, Venezuela
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00099333
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath